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1  | INTRODUC TION
Hepatic encephalopathy (HE) is a complex disease that is currently 
not fully understood. One of the presumed key factors in the patho-
genesis of HE is ammonia.1-4 Ammonia is produced by bacterial de-
amination of amino acids in the gastrointestinal tract.5 Ammonia 
diffuses into the portal circulation and is delivered to the liver, where 
it is detoxified via the urea cycle.6 When liver function is impaired 
or when portal blood bypasses the liver, ammonia can accumulate 
in blood.2,7 Hyperammonemia is toxic to the central nervous sys-
tem (CNS) because it alters amino acids (ie, glutamate and gluta-
mine), neurotransmission systems (ie, gamma-butyric acid), nitric 
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Abstract
Background: Hyperammonemia is one of the contributing factors of hepatic enceph-
alopathy (HE). Although blood ammonia concentrations are frequently measured in 
patients suspected of HE, systemic levels do not necessarily reflect the amount of 
ammonia	in	the	central	nervous	system.	Measuring	ammonia	in	cerebrospinal	fluid	
(CSF)	can	help	to	understand	HE	better	and	potentially	 improve	the	diagnosis	and	
follow-up of patients with HE.
Objectives: The objectives of this technical report were to evaluate the accuracy 
and precision of two commercial blood ammonia analyzers (Catalyst Dx, CatDX and 
Pocket	Chem	BA,	PocBA)	to	measure	CSF	ammonia	concentrations.
Methods: A	pool	of	normal	equine	CSF	was	spiked	with	concentrated	ammonia,	and	
a	series	of	six	spiked	samples	were	measured	in	parallel	with	both	CatDx	and	PocBA.
Results: CatDx	and	PocBA	data	correlated	excellently	with	but	differed	significantly	
from the spiked ammonia concentrations. These differences were smaller when am-
monia	CSF	concentrations	were	measured	with	the	PocBA	than	with	the	CatDx.	In	
addition,	values	obtained	with	the	PocBA	were	more	precise	than	those	measured	
with the CatDx, especially for low ammonia concentrations.
Conclusion: This in-house comparative study shows that ammonia concentrations 
in	spiked	equine	CSF	correlate	well	with	those	measured	by	two	commercial	blood	
ammonia	analyzers.	Nevertheless,	concentrations	obtained	with	the	PocBA	are	more	
accurate and more precise than those obtained with the CatDx, making the former 
device the preferred choice for clinical veterinary applications.
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oxide synthesis, and signaling transduction pathways, channels, and 
transporters.	Furthermore,	hyperammonemia	could	 lead	to	central	
energy deficits (ie, alpha-ketoglutarate), oxidative stress, and impair-
ment of axonal and dendrite growth.1,2
Although blood ammonia concentrations are frequently measured 
in people suspected of HE, these systemic levels do not necessarily 
reflect the levels in the CNS.8 The permeability of the blood-brain 
barrier	 (BBB)	 to	 ammonia	 is	 increased	 in	 human	 patients	 with	 HE	
secondary to liver disease, which could induce HE even if circulating 
ammonia concentrations are normal.9 Likewise, in dogs with portosys-
temic shunts (PSS), two research groups independently suggested that 
ammonia	concentrations	 in	cerebrospinal	 fluid	 (CSF)	are	higher	than	
those of healthy individuals.10,11 In the presence of HE secondary to 
PSS, a strong positive correlation between ammonia concentrations in 
blood	and	CSF	is	present.11 Although the exact ammonia concentra-
tions	in	CSF	could	be	irrelevant	in	most	clinical	situations,	this	knowl-
edge might be of interest when monitoring treatment responses in HE 
patients.	 However,	 current	 methods	 to	 determine	 ammonia	 in	 CSF	
are laborious, expensive, and require advanced equipment and exper-
tise.12	Moreover,	a	major	limitation	of	these	methods	is	that	they	are	
not intended for testing individual samples.13 Therefore, the aim of the 
current technical report was to compare the accuracy and precision 
of	ammonia	measurements	 in	CSF	using	 two	commercial	 laboratory	
devices validated only for blood.
2  | MATERIAL S AND METHODS
2.1 | Cerebrospinal fluid collection and storage
Cerebrospinal fluid of horses without neurologic disorders, eutha-
nized for reasons unrelated to this study, were used. Immediately 
after	 euthanasia,	 CSF	 was	 collected	 from	 the	 cerebellomedullary	
cistern	in	BD	(Becton	Dickinson)	vacutainers	without	additive.	Only	
macroscopically	normal	CSF,	with	a	microscopically	determined	cell	
count within normal limits (ie, <5 white blood cells/µL), was stored. 
Vacutainers were placed in a cool bag containing frozen gel packs im-
mediately	and	then	stored	at	−20°C	for	a	maximum	of	75	days.	The	
minimum	amount	of	CSF	necessary	to	perform	a	series	of	12	serial	
dilutions was calculated to anticipate potentially high measurement 
variation,	and	CSF	was	collected	until	this	amount	was	reached.
2.2 | Preparation of spiked cerebrospinal 
fluid samples
The	evening	before	comparative	evaluations	were	performed,	CSF	
was	thawed	slowly	overnight	at	4°C.	The	next	morning,	the	CSF	of	
all horses was pooled and kept in a closed container stored in a cool 
bag containing frozen gel packs.
Concentrated	 ammonia	 (Ammonia	 28%‐30%,	 Merck	 EMD	
Millipore)	 was	 used	 to	 spike	 at	 the	 selected	 ammonia	 concen-
trations	 in	the	CSF	pool.	Six	serial	dilution	sets	 (1200,	600,	300,	
150,	75,	37.50,	18.75	µmol/L)	were	prepared,	 and,	 for	 each	 set,	
a	 blank	 pooled	CSF	 sample	 served	 as	 the	 baseline	 control.	 As	 a	
consequence, per each set of serial dilutions, eight concentrations 
were tested. One serial dilution was prepared at a time. During the 
preparation of the serial dilutions, all samples were stored on dry 
ice and kept in capped tubes to minimize exposure to air until their 
analyses were performed.
2.3 | Quantification of ammonia in 
cerebrospinal fluid
Two commercial blood ammonia analyzers (Catalyst Dx [CatDx], 
IDEXX	 laboratories	 and	 Pocket	 Chem	 BA	 [PocBA],	 A.	 Menarini	
Diagnostics) were compared to measure ammonia concentrations in 
the	pooled	equine	CSF	spiked	with	ammonia.	Both	devices	use	a	mi-
crodiffusion‐based	colorimetric	assay.	More	specifically,	 test	strips	
are impregnated with an alkaline borate buffer that converts any dis-
solved ammonium (NH4
+) in the sample into gaseous ammonia (NH3). 
Ammonia then diffuses across a selectively permeable membrane 
and reacts with a pH indicator. After using the appropriate incuba-
tion times indicated by the manufacturer, the degree of color devel-
opment is proportional to the ammonia concentration in the sample. 
The analyzers differ in the pH indicator used, that is, bromophenol 
blue	for	the	CatDx	and	bromocresol	green	for	the	PocBA.
The	CatDx	is	a	nonportable	chemistry	analyzer	calibrated	at	21°C;	
therefore, analyses were performed in an air-conditioned room at a 
stable temperature. As ammonia is released during the clotting pro-
cess, it is recommended to measure ammonia in plasma or whole 
blood rather than in serum according to the manufacturer's guidelines. 
To	measure	ammonia	in	CSF,	the	sample	type	“other”	was	selected	on	
the	analyzer.	Before	 running	a	new	sample,	 the	ammonia	 slide	 (test	
slide) used for the previous sample was removed, and the analysis of a 
new series was only started when all samples from the previous series 
were removed from the machine. The latter measurements were taken 
to prevent ammonia from the slides or remaining sample from influ-
encing the measurements of the next sample (minimize risk for carry-
over). The detection range of ammonia in blood is 0-950 µmol/L. A 
sample	volume	of	300	µL	is	required	per	analysis.
The	other	device,	PocBA,	is	a	portable	blood	ammonia	analyzer.	
According to the manufacturer's guidelines, whole blood is recom-
mended for analysis. The detection range of ammonia in blood is 
8-285 µmol/L. The reagent strip packages were opened just prior to 
use, and we carefully avoided touching the sample retention layer. A 
20 µL sample volume was applied to the reagent strip.
The	pooled	and	spiked	CSF	sample	to	be	analyzed	(320	µL)	was	
placed in a sample cup for the CatDx, immediately after the dilution 
was	prepared.	 The	 sample	 (20	µL)	 for	 the	PocBA	was	 taken	 from	
the sample cup using a capillary tube just before its insertion into 
the CatDx. Two operators (ND and HdR) performed the analyses in 
parallel with both devices. Per serial dilution set (6 in total), analyses 
always started with the lowest concentration, and then, sequentially 
increasing concentrations were analyzed to minimize interference 
due	to	carry‐over.	The	analysis	time	needed	per	sample	was	3	min-
utes	55	seconds	and	3	minutes	20	seconds	for	the	CatDx	and	PocBA,	
respectively. All analyses were performed on the same day.
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2.4 | Statistical analysis
Statistical	analysis	was	performed	using	GraphPad	Prism	6	(GraphPad	
Software, Inc). Data were tested for normality using the D'Agostino 
& Pearson omnibus normality test. Correlations between the spiked 
concentrations and each of both laboratory analyzers were evaluated 
using the Spearman correlation tests. Wilcoxon matched-pairs signed-
rank tests were used to compare values between the spiked concen-
trations	 and	 each	 of	 both	 laboratory	 analyzers.	 Bland‐Altman	 plots	
were created to plot differences between each laboratory analyzer 
and the spiked ammonia concentration as well as between both labora-
tory	analyzers.	Bias	(mean	difference)	and	95%	(mean	difference	±	1.96	
SD) limits of agreement were calculated. The coefficient of variation 
(CV) was calculated to assess the precision of both laboratory devices. 
Each dilution of the six separate sets of serial dilutions was treated as 
an individual sample. P < .05 was considered statistically significant.
3  | RESULTS
CSF	from	six	healthy	horses	was	collected,	frozen,	and	subsequently	
pooled	 upon	 thawing;	 a	 total	 volume	of	 760	mL	 of	CSF	was	 thus	
obtained within 65 days.
After	spiking	a	sample	series	in	this	pool,	the	CatDx	and	the	PocBA	
analyzers showed excellent correlations with the spiked ammonia con-
centrations (r2	=	0.89	and	0.95,	respectively)	(Figure	1).	Nevertheless,	
the serial spiked ammonia concentrations differed significantly with the 
PocBA	and	CatDx	values	 (both	P < .0001) (Table 1). A more detailed 
evaluation	 with	 Bland‐Altman	 plots	 (Figure	 2A‐C)	 showed	 that	 bias	
among	the	ammonia	concentrations	measured	with	the	PocBA	analyzer	
and the actual spiked ammonia concentrations were closer to zero than 
those	measured	with	the	CatDx	analyzer,	which	implies	that	the	PocBA	
measurements	were	more	accurate	than	those	of	the	CatDx.	For	CSF	
ammonia concentrations below 150 µmol/L, mild overestimation was 
seen	with	the	PocBA	analyzer,	whereas	at	higher	ammonia	concentra-
tions (>150 µmol/L), mild underestimation was observed. In contrast, 
the CatDx analyzer underestimated the ammonia concentrations over 
the entire concentration range tested, and the difference became more 
pronounced with increasing ammonia concentrations.
The	coefficient	of	variations	(CVs)	for	the	CatDx	and	PocBA	ana-
lyzers	ranged	from	0.09	to	1.55	and	from	0.03	to	0.35,	respectively	
(Table	2).	Measurements	performed	with	the	PocBA	analyzer	were,	
therefore, more precise than those performed with the CatDx ana-
lyzer.	Moreover,	ammonia	concentrations	<75	µmol/L	in	equine	CSF	
could not be measured precisely with the CatDx analyzer (Table 2).
4  | DISCUSSION
The present technical report demonstrates that ammonia can be 
measured	in	equine	CSF	with	the	CatDx	and	PocBA	commercial	blood	
ammonia	analyzers.	Both	devices	generated	ammonia	concentrations	
F I G U R E  1  A	correlation	plot	showing	the	relationship	between	the	spiked	concentration	of	ammonia	in	equine	CSF	and	the	measured	
concentration	with	the	Catalyst	Dx	(CatDx)	and	Pocket	Chem	BA	(PocBA)	blood	ammonia	analyzers.	The	CatDx	(r2	=	0.89)	and	PocBA	
(r2 = 0.95) analyzers showed excellent correlations with the spiked ammonia concentrations
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that correlated with the spiked ammonia concentrations. A similar de-
gree	of	correlation	for	the	CatDx	and	PocBA	analyzers	was	expected	
since they have a microdiffusion-based colorimetric assay in common. 
Despite this correlation, the values measured with both devices dif-
fered significantly from the spiked concentrations. However, the mean 
difference between the spiked ammonia concentration and the con-
centration	measured	with	the	PocBA	analyzer	was	smaller	than	that	
measured with the CatDx analyzer. Quantifications performed with 
the	PocBA	analyzer	were	more	accurate	overall.	Moreover,	in	case	of	
clinically	relevant	ammonia	excess	(ie,	>150	µmol/L),	PocBA	underesti-
mated	concentrations	less	than	the	CatDx	analyzer,	making	the	PocBA	
analyzer	more	 reliable	 for	monitoring	patients	with	HE.	The	PocBA	
measurements were also more precise than those of the CatDx, espe-
cially for the low ammonia concentrations. To evaluate the precision of 
both laboratory devices better, more samples for each concentration 
should ideally be tested, and analysis should be performed over multi-
ple days. Even though within-day precision, as evaluated in this study, 
gives a notion about repeatability of the results, assessment of both 
within-day and between-day precision would have added more value 
to the evaluation of precision for both devices.14
A	 significant	 advantage	 of	 the	 PocBA	 analyzer	 is	 that	 it	 is	 a	
hand‐held	device.	Blood	ammonia	measurements	are	known	to	be	
challenging. Ammonium ions are labile and preanalytical errors can 
occur by ammonia formation from endogenous metabolites in stored 
samples or by environmental contamination.6,8 Directly measuring 
ammonia	 concentrations	 from	CSF	 patient	 samples	 decreases	 the	
potential risk of preanalytical errors. The CatDx analyzer, on the 
other hand, can simultaneously measure additional clinical biochem-
istry variables on the same sample. However, this advantage does 
not outweigh the disadvantages of being a nonportable device that 
needs	 to	 be	 calibrated	 at	 21°C	 and	 consequently	 requires	 a	 tem-
perature-controlled laboratory. The sample volume required for the 
CatDx	analyzer	is	300	µL,	which	is	15‐fold	higher	than	for	the	PocBA	
analyzer. This, however, does not seem to be a clinically relevant 
difference.	A	total	of	1	mL	CSF/5	kg	of	body	weight	can	be	collected	
in	animals;	thus	300	µL	is	feasible,	even	in	small	animals.	In	patients	
where	 only	 a	 very	 small	CSF	 sample	 can	 be	 collected,	 the	PocBA	
analyzer	has	an	advantage	over	the	CatDx	analyzer.	Finally,	analysis	
times of less than 4 minutes were similar for both devices, and thus, 
were not considered to be a discriminating factor.
One	limitation	of	the	PocBA	analyzer	was	that	it	has	a	relatively	
low upper quantitation limit (285 µmol/L) compared with that of the 
CatDx analyzer (950 µmol/L). However, this approximatively three-
fold narrower dynamic range could be readily overcome by appro-
priate sample dilution. Nevertheless, additional dilution adds to the 
costs and time of the analysis and increases the risk for measurement 
errors.15	Ammonia	concentrations	detected	in	the	CSF	of	dogs	with	
PSS	and	concurrent	HE	were	reported	to	all	be	below	300	µmol/L.11 
As	a	consequence,	it	appears	that	the	detection	limit	of	the	PocBA	
analyzer would be sufficient to measure ammonia concentrations in 
most (if not all) clinical patients. In this technical report, preanalyt-
ical	errors	were	minimized	by	collecting	CSF	immediately	following	
euthanasia and by direct cooling of the samples. Regarding the as-
pect	of	storage	stability	on	ammonia	concentrations	in	CSF	patient	
samples, a previous study showed no significant change in ammo-
nia	concentrations	when	human	CSF	was	stored	at	−20°C	for	up	to	
1 month.13 Ammonia concentrations measured in the blank samples 
of	 the	CSF	pool	 that	 served	as	baseline	control	were	all	very	 low.	
The one blank sample with an ammonia concentration of 67 µmol/L 
when	measured	the	PocBA	analyzer,	revealed	an	ammonia	concen-
tration of 0 µmol/L when measured in parallel with the CatDx ana-
lyzer.	The	 low	ammonia	CSF	concentrations	after	storage	of	up	to	
75	days	at	−20°C	suggests	that	the	storage	time	did	not	affect	the	
ammonia concentration. In plasma, it is known that ammonia forma-
tion is a continuous process; changes in ammonia concentrations are 
more impacted by storage duration than storage temperatures.16,17
For	current	validation	purposes,	equine	rather	than	canine	CSF	
was chosen, for the practical reason of enabling the collection of 
a	relatively	 large	volume	of	CSF	within	an	acceptable	time	frame.	
However, it should be mentioned that for ammonia measurements, 
canine research dominates the veterinary literature. Cerebrospinal 
fluid characteristics in healthy dogs and horses, such as color and 
clarity, and the presence of white blood cells, are similar. The upper 
limit of the total protein content, however, is fourfold higher in 
horses compared with dogs (<100 mg/dL vs <25 mg/dL, respec-
tively).18 Even though this is a significant difference, ammonia does 
not bind to proteins. Proteins also do not influence the conversion 
of dissolved ammonium ions into gaseous ammonia. Therefore, 
interspecies differences are not likely to influence ammonia con-
centrations, and we postulate that it is very likely that our data in 
equine	 CSF	 could	 be	 extrapolated	 for	 canine	 CSF.	 A	 recent	 clin-
ical study from our group looking at dogs with extrahepatic PSS 
with	CSF	ammonia	measurements	 and	using	 the	 same	devices	 as	
performed in the current study supported our hypothesis. In that 
study,	a	correlation	between	CatDx	and	PocBA	analyzer	measure-
ments was also found, and the mean ammonia concentration in ca-
nine	CSF	measured	with	the	PocBA	analyzer	(106.6	±	55.6	µmol/L)	
TA B L E  1  Mean	cerebrospinal	fluid	ammonia	concentrations	
measured with both commercial blood ammonia analyzers (six 
samples were analyzed for each concentrations)
Spiked ammonia 
concentration 
(µmol/L)
CatDx
Mean (range) 
(µmol/L)
PocBA
Mean (range) (µmol/L)
0.00 5.50 (0-17) 39.33	(30‐67)
18.75 11.33	(0‐35) 58.00 (44-84)
37.50 15.67 (7-49) 74.17	(59‐93)
75.00 25.00	(14‐33) 112.00 (106-128)
150.00 67.83	(47‐121) 171.33	(166‐179)
300.00 116.17	(107‐136) 265.40	(233‐high)
600.00 286.00	(222‐322) NA
1200.00 602.33	(400‐706) NA
Note: NA:	not	applicable	because	the	upper	limit	of	detection	of	PocBA	
is 285 µmol/L.
Abbreviations:	CatDX,	Catalyst	Dx;	PocBA,	Pocket	Chem	BA.
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F I G U R E  2  Bland‐Altman	plots	of	the	differences	between	the	spiked	ammonia	concentrations	and	the	concentrations	measured	with	(A)	
the	Catalyst	Dx	(CatDx);	(B)	the	Pocket	Chem	BA	(PocBA);	and	(C)	both	the	PocBA	and	CatDx	analyzers.	For	each	plot	the	upper	and	lower	
dashed lines represent the 95% limits of agreement. The solid line indicates the mean difference (bias)
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was consistently higher than that measured using the CatDx ana-
lyzer	(60.1	±	42.9	µmol/L).11
The	fact	that	CSF	ammonia	can	be	measured	with	commercially	
available laboratory devices boosts further research. Studies used 
to gain insight into how ammonia should be measured to study the 
pathogenesis of HE have become more feasible.
This	study	documents	that	CSF	ammonia	quantified	with	com-
mercial	 blood	 ammonia	 analyzers	 correlated	 with	 CSFs	 contain-
ing	spiked	ammonia	concentrations.	Values	obtained	with	the	PocBA	
analyzer were more accurate and precise than with the CatDx ana-
lyzer.	Both	the	CatDx	and	PocBA	analyzers	are	fast,	easy‐to‐use,	and	
inexpensive	devices	with	PocBA	being	a	hand‐held	analyzer.	Future	
studies are needed to establish reference intervals for ammonia in 
the	CSF	of	different	species	using	these	analyzers.
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TA B L E  2   The coefficient of variation (CV) and SD of the 
two commercial blood ammonia analyzers used to measure 
cerebrospinal fluid ammonia concentrations (six samples were 
analyzed at each concentration)
Spiked ammonia 
concentration 
(µmol/L)
CatDx
CV (Standard 
deviation)
PocBA
CV (Standard 
deviation)
0.00 1.55	(8.53) 0.35	(13.95)
18.75 1.12 (12.68) 0.24	(13.81)
37.50 1.05 (16.46) 0.17 (12.58)
75.00 0.28 (6.99) 0.07 (8.10)
150.00 0.41 (27.59) 0.03	(4.46)
300.00 0.09 (10.68) 0.08 (21.76)
600.00 0.12	(35.48) NA
1200.00 0.18 (109.00) NA
Note: NA:	not	applicable	because	the	upper	limit	of	detection	of	PocBA	
is 285 µmol/L.
Abbreviations:	CatDX,	Catalyst	Dx;	PocBA,	Pocket	Chem	BA.
